Skip to main content

Table 4 Incremental Cost-Effectiveness Ratios Comparing SBRT versus sorafenib at the Base Case

From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

Various cost Sorafenib SBRT
QALYs (years) 3.07 2.81
Incremental QALY gained (years) 0.26 -
Lifetime cost (US$) 2166,079.7 1,197,039.2
Incremental cost (NT$) 969,041 -
Cost/effectiveness 704,857.96 426,117.13
ICER (NT$) 3,788,238
Cost-effectiveness threshold (NT$) 2,213,145
Is SBRT cost-effective? No